Compare Novavax Inc (NVAX) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Orion Office REIT Inc — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Orion Office REIT Inc trades at $2.55 (market cap $149.46M). The key difference: Novavax Inc is far larger — about 10.8× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.05% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | ONL | |
|---|---|---|
Market Cap | $1.62B | $149.46M |
Sector | Health | Real Estate |
52-Week High | $11.19 | $3.00 |
52-Week Low | $6.22 | $1.93 |
Enterprise Value | $1.20B | $566.39M |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
ONL trades at $2.66, down 1.85% with a bearish technical signal. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics include P/S of 1.04 and P/B of 0.24, indicating potential undervaluation. Recent news highlights strategic portfolio repositioning and a deep-value opportunity in office REITs.
Outlook remains challenging with negative profitability and high debt levels, but analyst consensus is split 50/50 buy/hold. Key risks include ongoing revenue declines and office sector headwinds, while potential upside exists if turnaround efforts gain traction amid stabilized office demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
